Results 151 to 160 of about 6,463,095 (311)

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

The role of dexamethasone during treatment phases in glioblastoma: Insights from a retrospective observational study

Brain and Spine
Background: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. Dexamethasone (DEX) is commonly used to manage peritumoral edema, but its impact on overall survival (OS) and progression-free survival (PFS) remains unclear across ...
Juliane Göbel, Maximilian Scheer, Clemens Kirchner, Sandra Leisz, Julian Prell, Christian Strauss, Sebastian Simmermacher, Stefan Rampp   +7 more
doaj   +1 more source

Meta-analysis of progression-free survival.

, 2013
Meta-analysis of progression-free survival.
André Bacellar Costa Lima (346937), Ligia T. Macedo (346938), André Deeke Sasse (346939)   +2 more
core   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Progression-free survival by subgroup (FAS).

, 2015
Progression-free survival by subgroup (FAS).
Caicun Zhou (300936), Jianying Zhou (506073), Nong Xv (830098), Dong Wang (73290), Fenlai Tan (830099), Yinxiang Wang (830100), Yong Song (286107), Shucai Zhang (829370), Rongcheng Luo (311459), Chunhong Hu (105578), Xingsheng Hu (830096), Lieming Ding (830101), Xiaoqing Liu (196900), Qiang Li (8118), Jie Wang (16762), Yan Sun (22436), Yuankai Shi (495418), Shukui Qin (830097), Jifeng Feng (432175), Li Zhang (8200)   +19 more
core   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Extended Survival and Prognostic Factors in Endometrial Cancer: A Multivariate Cox Regression Analysis

Clinical and Experimental Obstetrics & Gynecology
Background: Endometrial cancer (EC) is the third most prevalent neoplasm among women in Spain and the most frequent malignancy of the female genital tract. The primary risk factors are associated with increased estrogen levels.
Irene Valencia Téllez, Laura De Pablo Zamora, María Castillo Lara, Claudia Vivas Flores, Carlos Vega Reina, Juan Jesús Fernández Alba   +5 more
doaj   +1 more source

Forest plot—Progression-free Survival—all trials.

, 2017
Forest plot—Progression-free Survival—all trials.
Andrew J. Martin (3769216), Nick Pavlakis (783392), David L. Chan (783391), David Goldstein (57135), Timothy J. Price (783394), Katrin M. Sjoquist (3769213), Yung-Jue Bang (73319), Yoon-Koo Kang (3409571)   +7 more
core   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source